WGS genedx.com Company Cash on Hand

Graphic logo of genedx.com (WGS)

High barriers to entry, driven by its IT platform and stringent CLIA standards, define the financial stability of GeneDx Holdings Corp. (WGS). Cash reserve dynamics demonstrate current liquidity, where 0.17 reflects the latest metric value. A steady order flow across US laboratories confirms the demand for precision medicine, while technological superiority in diagnosing rare pathologies allows the company to confidently maintain its market leadership.

WGS - Sema4 Company Cash on Hand over the range 04/28/2023 - 11/21/2026

Financial and market metric breakdowns for GeneDx Holdings (WGS)

- stock value and consensus price forecast:
Fundamental company valuation:genedx.com WGS
Signature product of GeneDx

This metric measures the total volume of liquid assets on the balance sheet, determining the business's ability to cover operating expenses without seeking external financing. Analyzing the level of cash reserves allows for an assessment of capital deficiency risk, which is critically important for GeneDx Holdings Corp. (WGS), as maintaining laboratories requires significant investment until high margins are achieved through database scaling.

Main competitors

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|RARE: Company Cash Volume|BEAM - Company Liquid Assets|SRPT (Sarepta Therapeutics) - Company Cash Volume|Company Cash on Hand Twist Bioscience Inc (TWST)|Company Cash Volume TXG|Company Liquid Assets Intellia|Stoke - Company Cash on Hand|BLFS: Company Cash and Cash Equivalents|Wave Life Sciences Corp - Company Cash Volume|Maze Therapeutics, Inc. (MAZE) - Company Cash on Hand|Sionna Therapeutics Inc (SION) - Company Cash Funds|Company Cash on Hand Prime Medicine Corp|Company Cash Funds tayshagtx.com|QURE - Company Cash Position|Company Cash on Hand MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume